Prof. Dr. med. Hermann Einsele

Medizinische Klinik und Poliklinik II,
Medizinische Fakultät

Julius Maximilians-Universität Würzburg
Oberdürrbacher Str. 6
97080 Würzburg
Phone:  +49 931 20140000
Fax: +49 931 201640001
E-Mail: einsele_h@ukw.de

University training and degree

1982 – 84 Studies of Medicine Eberhard Karls University of Tübingen
1980 – 82
Studies of Medicine; Lord Owen’s University Manchester and Guy’s Hospital London
1977 – 80
Studies of Medicine Eberhard Karls University of Tübingen

Advanced academic qualifications

1996 Board Examination in Hematology and Oncology
1992
Habilitation at the University of Tübingen
1991 
Venia legendi for Internal Medicine
1986
MD thesis at the University of Tübingen, Institute for Experimental and Clinical Pharmacology and Toxicology (Supervisor: Prof. Dr. Dr. h.c. H. Remmer, Prof. Dr. Dr. h.c. H.D. Waller); grade: “summa cum laude
1984
Approbation as physician

Postgraduate professional career

06/2001 – 12/2004 Head of the Allogeneic Stem Cell Transplantation Programme (Tübingen)
06/1999 – 12/2004
Associate Professor, Eberhard Karls University Tübingen
01/1993 – 06/1999
Assistant Professor, Eberhard Karls University Tübingen, Department Internal Medicine II (Director: Prof. Dr. L. Kanz)
04/1984 – 01/1993
Scientific Assistant, Eberhard Karls University Tübingen

Since 2015 Vice President of the JMU Würzburg
Since 2015 
Member of the Faculty Advisory Board of the Faculty of Medicine, Friedrich-Schiller-University Jena
Since 2014
Member of the Academy of Science (Mainz)
2011 – 2015
Vice Dean of the Faculty of Medicine, University of Würzburg
2012
Nobel Lecturer Stem Cell Biology/Transplantation, Nobel Forum Karolinska
Institute
2011 
Honory Fellow of the Royal College of Pathology (London)
2003
Visiting Professor, City of Hope Hospital, Duarte, USA
2003
Van Bekkum Award of the European Group for Blood and Marrow
Transplantation (EBMT)
2000
Visiting Professor, City of Hope Hospital, Duarte, USA

a) Articles published by outlets with scientific quality assurance, book publications and works accepted for publication, but not yet published

1. Gudipati V, Rydzek J, Doel-Perez I, Dos Reis Gonçalves V, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H, Hudecek M, Huppa JB. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat Immunol 2020 Jul 6. doi: 10.1038/s41590-020-0719-0.

2. Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol 2020 Jan 2:JCO1902657.

3. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica 2019;104(12):2358-2360.

4. Querques I, Mades A, Zuliani C, Miskey C, Alb M, Grueso E, Machwirth M, Rausch T, Einsele H, Ivics Z, Hudecek M, Barabas O. A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nat Biotechnol 2019;37(12):1502-1512.

5. Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun 2019;10(1):5387.

6. Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia 2019;33(11):2710-2719.

7. Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia 2017;31(10):2161-2171.

8. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015;373(7):621-31.

9. Stemberger C, Graef P, Odendahl M, Albrecht J, Dössinger G, Anderl F, Buchholz VR, Gasteiger G, Schiemann M, Grigoleit GU, Schuster FR, Borkhardt A, Versluys B, Tonn T, Seifried E, Einsele H, Germeroth L, Busch DH, Neuenhahn M. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014;124(4):628-37.

10. Einsele H, Hamprecht K. Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? Lancet 2003;362(9393).